^
    Back
    Association details:
    Biomarker:ETV6-NTRK3 fusion
    Cancer:Breast Cancer
    Drug:Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    JCO Precis Oncol
    Title:

    Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma

    Excerpt:
    The 14-year-old reported here, despite being very heavily pre-treated for 6 years and having a high burden of disease, achieved an almost immediate and complete response to larotrectinib that remains ongoing with minimal toxicity.
    DOI:
    10.1200/PO.17.00034